PriceTargets.com logo

Oncorus - ONCR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.25
  • Forecasted Upside: 1,149.70%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.42 As of 01/27/2023 10:32 AM ET
▼ -0.0097 (-2.26%)

This chart shows the closing price for ONCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncorus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCR

Analyst Price Target is $5.25
▲ +1,149.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oncorus in the last 3 months. The average price target is $5.25, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 1,149.70% upside from the last price of $0.42.

This chart shows the closing price for ONCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Oncorus. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2022HC WainwrightDowngradeBuy ➝ NeutralLow
11/30/2022Chardan CapitalDowngradeBuy ➝ NeutralLow
11/30/2022Piper SandlerDowngradeOverweight ➝ Neutral$6.00 ➝ $2.00Low
11/2/2022Piper SandlerLower Target$12.00 ➝ $6.00Low
6/15/2022Chardan CapitalInitiated CoverageBuy$5.00High
5/18/2022Piper SandlerLower TargetOverweight$40.00 ➝ $12.00Medium
3/28/2022HC WainwrightInitiated CoverageBuy$7.00High
3/10/2022Maxim GroupLower Target$20.00 ➝ $7.00High
3/16/2021Maxim GroupInitiated CoverageBuy$35.00Medium
10/27/2020Evercore ISIInitiated CoverageOutperform$35.00High
10/27/2020Jefferies Financial GroupInitiated CoverageBuy$22.00High
10/27/2020Piper SandlerInitiated CoverageOverweight$40.00High
(Data available from 1/27/2018 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oncorus logo
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.42
Low: $0.42
High: $0.42

50 Day Range

MA: $0.40
Low: $0.24
High: $0.68

52 Week Range

Now: $0.42
Low: $0.23
High: $3.68

Volume

6,906 shs

Average Volume

668,361 shs

Market Capitalization

$10.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncorus?

The following Wall Street research analysts have issued stock ratings on Oncorus in the last twelve months: Chardan Capital, HC Wainwright, Maxim Group, and Piper Sandler.
View the latest analyst ratings for ONCR.

What is the current price target for Oncorus?

4 Wall Street analysts have set twelve-month price targets for Oncorus in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 1,121.5%. Maxim Group has the highest price target set, predicting ONCR will reach $7.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $2.00 for Oncorus in the next year.
View the latest price targets for ONCR.

What is the current consensus analyst rating for Oncorus?

Oncorus currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ONCR, but not buy more shares or sell existing shares.
View the latest ratings for ONCR.

What other companies compete with Oncorus?

Other companies that are similar to Oncorus include Aytu BioPharma, Imunon, Cyclacel Pharmaceuticals, Sonnet BioTherapeutics and Vascular Biogenics. Learn More about companies similar to Oncorus.

How do I contact Oncorus' investor relations team?

The company's listed phone number is 857-320-6400 and its investor relations email address is [email protected] The official website for Oncorus is www.oncorus.com. Learn More about contacing Oncorus investor relations.